Maxim Group set a $5.00 price target on Sophiris Bio (NASDAQ:SPHS) in a report published on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the company. HC Wainwright set a $6.00 price target on Sophiris Bio and gave the stock a buy rating in a report on Wednesday, January 17th. ValuEngine raised Sophiris Bio from a strong sell rating to a sell rating in a report on Friday, December 15th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $6.00.

How to Become a New Pot Stock Millionaire

Sophiris Bio stock traded up $0.04 during trading on Thursday, hitting $2.18. The stock had a trading volume of 138,741 shares, compared to its average volume of 193,542. The company has a debt-to-equity ratio of 0.60, a current ratio of 13.37 and a quick ratio of 13.37. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $2.95. The firm has a market cap of $65.04, a PE ratio of -7.38 and a beta of 1.30.

Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings results on Wednesday, March 21st. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). research analysts anticipate that Sophiris Bio will post -0.58 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of SPHS. Millennium Management LLC acquired a new position in Sophiris Bio in the 4th quarter worth about $453,000. Goldman Sachs Group Inc. acquired a new position in Sophiris Bio in the 4th quarter worth about $312,000. Virtu Financial LLC increased its holdings in Sophiris Bio by 389.7% in the 4th quarter. Virtu Financial LLC now owns 169,790 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 135,119 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Sophiris Bio by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 731,437 shares of the biopharmaceutical company’s stock worth $1,609,000 after purchasing an additional 7,600 shares in the last quarter. 6.37% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/sophiris-bio-sphs-given-a-5-00-price-target-at-maxim-group/1960554.html.

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.